🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
0.8941
-0.1359 (-13.19%)
At close: Nov 19, 2026, 4:00 PM EST
0.8975
+0.0034 (0.38%)
After-hours: Nov 19, 2026, 7:51 PM EST

INmune Bio Statistics

Total Valuation

INmune Bio has a market cap or net worth of $27.68 million. The enterprise value is $12.56 million.

Market Cap27.68M
Enterprise Value 12.56M

Important Dates

The last earnings date was Thursday, November 5, 2026, after market close.

Earnings Date Nov 5, 2026
Ex-Dividend Date n/a

Share Statistics

INmune Bio has 30.96 million shares outstanding. The number of shares has increased by 13.79% in one year.

Current Share Class 30.96M
Shares Outstanding 30.96M
Shares Change (YoY) +13.79%
Shares Change (QoQ) +4.08%
Owned by Insiders (%) 9.69%
Owned by Institutions (%) 14.79%
Float 27.96M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio n/a
Forward PS n/a
PB Ratio 1.38
P/TBV Ratio 1.53
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 6.41, with a Debt / Equity ratio of 0.07.

Current Ratio 6.41
Quick Ratio 6.19
Debt / Equity 0.07
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -76.71% and return on invested capital (ROIC) is -48.56%.

Return on Equity (ROE) -76.71%
Return on Assets (ROA) -40.49%
Return on Invested Capital (ROIC) -48.56%
Return on Capital Employed (ROCE) -95.59%
Weighted Average Cost of Capital (WACC) 9.03%
Revenue Per Employee n/a
Profits Per Employee -$793,619
Employee Count21
Asset Turnover n/a
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -40.39% in the last 52 weeks. The beta is 0.94, so INmune Bio's price volatility has been similar to the market average.

Beta (5Y) 0.94
52-Week Price Change -40.39%
50-Day Moving Average 1.64
200-Day Moving Average 1.60
Relative Strength Index (RSI) 23.35
Average Volume (20 Days) 372,533

Short Selling Information

The latest short interest is 2.66 million, so 8.59% of the outstanding shares have been sold short.

Short Interest 2.66M
Short Previous Month 2.89M
Short % of Shares Out 8.59%
Short % of Float 9.51%
Short Ratio (days to cover) 9.96

Income Statement

Revenue n/a
Gross Profit n/a
Operating Income -17.77M
Pretax Income -16.67M
Net Income -16.67M
EBITDA -17.52M
EBIT -17.77M
Earnings Per Share (EPS) -$0.62
Full Income Statement

Balance Sheet

The company has $16.33 million in cash and $1.21 million in debt, with a net cash position of $15.12 million or $0.49 per share.

Cash & Cash Equivalents 16.33M
Total Debt 1.21M
Net Cash 15.12M
Net Cash Per Share $0.49
Equity (Book Value) 18.07M
Book Value Per Share 0.65
Working Capital 15.79M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$12.91 million and capital expenditures -$573,000, giving a free cash flow of -$13.49 million.

Operating Cash Flow -12.91M
Capital Expenditures -573,000
Depreciation & Amortization 247,000
Net Borrowing n/a
Free Cash Flow -13.49M
FCF Per Share -$0.44
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

INmune Bio does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
FCF Payout Ratio n/a
Buyback Yield -13.79%
Shareholder Yield -13.79%
Earnings Yield -69.21%
FCF Yield -48.72%

Analyst Forecast

The average price target for INmune Bio is $6.50, which is 626.99% higher than the current price. The consensus rating is "Strong Buy".

Price Target $6.50
Price Target Difference 626.99%
Analyst Consensus Strong Buy
Analyst Count 3
Revenue Growth Forecast (3Y) 682.00%
EPS Growth Forecast (3Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a
Graham Formula Value n/a
Graham Formula Upside n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date n/a
Split Type n/a
Split Ratio n/a

Scores

INmune Bio has an Altman Z-Score of -8.38 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -8.38
Piotroski F-Score 2